Acute Myeloid Leukemia

The Acute Myeloid Leukemia pipeline: 123 tracked drugs, 17 approved for this indication.

17 approved / phase 413 Phase 33 Phase 2/38 Phase 228 Phase 1/247 Phase 17 preclinical / unstaged

Compare the share prices of listed companies in Acute Myeloid Leukemia →

Total attributable cost

$4.5B

$199,362/patient

Drug spend

Not yet sourced

How this is calculated ↗

All stages, newly diagnosed (2026 incidence estimate) · US

The Acute Myeloid Leukemia pipeline

Key trial results for every approved and late-stage drug: Acute Myeloid Leukemia results by drug.

← all assets